Literature DB >> 9342171

Role of cytochrome P450 enzymes in drug-drug interactions.

F P Guengerich1.   

Abstract

Many adverse drug-drug interactions are attributable to pharmacokinetic problems and can be understood in terms of alterations of P450-catalyzed reactions. Much is now known about the human P450 enzymes and what they do, and it has been possible to apply this information to issues related to practical problems. A relatively small subset of the total number of human P450s appears to be responsible for a large fraction of the oxidation of drugs. The three major reasons for drug-drug interactions involving the P450s are induction, inhibition, and possibly stimulation, with inhibition appearing to be the most important in terms of known clinical problems. With the available knowledge of human P450s and reagents, it is possible to do in vitro experiments with drugs and make useful predictions. The results can be tested in vivo, again using assays based on our knowledge of human P450s. This approach has the capability of not only improving predictions about which drugs might show serious interaction problems, but also decreasing the number of in vivo interaction studies that must be performed. These approaches should improve with further refinement and technical advances.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342171     DOI: 10.1016/s1054-3589(08)60200-8

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  38 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Drug Interactions with Antiretrovirals.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

Review 3.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

4.  Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.

Authors:  Jackie C Bloomer; Mike Nash; Alison Webb; Bruce E Miller; Aili L Lazaar; Claire Beaumont; William J Guiney
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

5.  CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

Review 6.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 7.  Potential of pharmacokinetic profiling for detecting herbal interactions with drugs.

Authors:  Veronika Butterweck; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation.

Authors:  Abdul Naveed Shaik; Barbara W LeDuc; Ansar A Khan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

9.  Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies.

Authors:  P Bonnabry; J Sievering; T Leemann; P Dayer
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.

Authors:  Eva Bredberg; Tommy B Andersson; Lars Frison; Annelie Thuresson; Susanne Johansson; Maria Eriksson-Lepkowska; Marita Larsson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.